Avastin plus chemotherapy demonstrated statistically significant OS in cervical cancer

In the GOG-0240 study, Avastin plus chemotherapy was proven to increase OS by 3.9 months (16.8 months vs 12.9 months) vs chemotherapy alone (HR=0.74 [95% CI, 0.58–0.94], P=0.0132).[1]

CC=cervical cancer; OS=overall survival; GOG=Gynecologic Oncology Group; HR=hazard ratio; CI=confidence interval.

*Insurer/payer policies are subject to change. The completion and submission of coverage or reimbursement-related documentation are the responsibility of the patient and the healthcare provider. Genentech makes no guarantee concerning coverage or reimbursement for any service or item. Inclusion of a plan or product is not intended to imply a recommendation of a particular plan or product. Coverage percentage shown is a weighted average based on national patients treated for Avastin.
As of 01/01/2021, national coverage for Avastin is 85%+.